Slingshot members are tracking this event:

Bayer (BAYRY) Announces Regulatory Submission of Regorafenib in Second-Line Treatment of Liver Cancer in U.S, Europe, and Japan

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Regulatory Submission, Regorafenib, Second-line Treatment, Liver Cancer, U.s, Japan, Europe, Fda, Ema, Phase 3, Resorce